Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, is an intractable disease of the gastrointestinal tract. Multiple environmental factors, including food ingredients, have been implicated in the development of these diseases. For example, animal fat-rich diets are predisposing factors for ulcerative colitis, whereas n-3 unsaturated fatty acids such as docosahexaenoic acid (DHA) show protective effects in experimental colitis and are negatively correlated with the incidence of ulcerative colitis and Crohn's disease. Given that DHA exhibits agonistic activity on retinoid X receptor (RXR), activation of RXR could be a therapeutic strategy for IBD. However, conventional full RXR agonists are known to show considerable adverse effects. We therefore took advantage of a partial RXR agonist, CBt-PMN, to minimize the adverse effects, and evaluated its efficacy in dextran sodium sulfate-induced colitis. Administration of CBt-PMN efficiently ameliorated the symptoms of colitis. This effect was attributed to the down-regulation of pro-inflammatory cytokines such as Tnf and Il6 in colon-infiltrating monocytes. Down-regulation of pro-inflammatory cytokines by CBt-PMN was also evident in lipopolysaccharide-stimulated bone marrow-derived macrophages (BMDMs). Among many RXR-associated nuclear receptors, activation of peroxisome proliferator-activated receptor δ (PPARδ) and nuclear hormone receptor 77 (Nur77) suppressed cytokine production by BMDMs. These observations suggest that the activation of PPARδ/RXR and Nur77/RXR heterodimers by CBt-PMN through the permissive mechanism is responsible for diminishing the monocyte-mediated inflammatory response in the gut. Our data highlight the importance of RXR activation in the regulation of colitis.
Introduction
The number of patients with inflammatory bowel disease (IBD) has been increasing in developed countries for decades; the prevalence of IBD exceeded 0.3% in populations residing in North America, Oceania and Europe (1) . Both genetic and environmental factors including dietary habits are implicated in the development of IBD (2, 3) . For instance, intake of a high-fat diet containing cholesterol and animal fat (the so-called westernized diet) was considered as a predisposing factor for IBD (4) , whereas prospective cohort studies demonstrated that intake of n-3 polyunsaturated fatty acids such as docosahexaenoic acid (DHA) negatively correlates with the incidence of ulcerative colitis and Crohn's disease (5, 6) . Moreover, oral administration of DHA to dextran sulfate sodium (DSS)-induced IBD model mice attenuates inflammatory colitis (7) . DHA has been well documented to suppress the production of prostaglandins and leukotrienes from arachidonic acid (8) . Furthermore, DHA-derived epoxydocosapentaenoic acids possess an anti-inflammatory property (9) . However, the anti-inflammatory mechanisms of DHA are yet to be fully understood. Furthermore, a previous study demonstrated that DHA serves as a ligand for retinoid X receptor (RXR) (10) . RXR is a nuclear receptor that regulates transcription of target genes. This nuclear receptor is activated by binding of endogenous ligands such as 9-cis retinoic acid, in addition to DHA (11) . RXR forms either homodimers or heterodimers with other nuclear receptors including peroxisome proliferator-activated receptor (PPAR), liver X receptor (LXR), constitutive androstane receptor (CAR), nuclear hormone receptor 77 (Nur77) and nur-related factor 1 (Nurr1) (12) . These heterodimers can be concomitantly activated by single RXR ligands, which is termed as a 'permissive mechanism' (13) . RXR agonists have been considered as promising candidates for the treatment of multiple diseases including cancer, atherosclerosis, type 2 diabetes and Parkinson's disease (14) (15) (16) (17) . Nevertheless, considerable adverse effects such as hepatomegaly and blood triglyceride elevation hamper the development of RXR full agonists as therapeutic drugs, the except for bexarotene, which has been approved to treat cutaneous T-cell lymphoma (14) . To deal with this issue, we previously generated an RXR partial agonist, CBt-PMN, whose maximum efficacy on RXR activation is ~75% relative to that of the full agonist, bexarotene (17) . While CBt-PMN successfully reduced the adverse effects such as hepatomegaly and blood triglyceride elevation (17) , transcriptional activation by CBt-PMN towards RXR is more potent (EC 50 : 0.15 µM) than that of DHA (EC 50 : 5-10 µM) (10). Here, we report that CBt-PMN confers protection from development of DSS-induced colitis by suppressing production of inflammatory cytokines in myeloid cell lineages.
Methods

Animal experiments
C57BL/6J mice (male 5 to 7 weeks old) were purchased from CLEA Japan (Tokyo, Japan) or Sankyo Labo Service Corporation (Tokyo, Japan). All studies were approved by the Animal Care Committees of Keio University and Okayama University. Mice received 2% DSS (molecular weight: 36 000-50 000, MP Biomedicals, Santa Ana, CA, USA) in drinking water for 6 days, followed by normal water for 3 or 6 days. CBt-PMN and bexarotene were synthesized as shown previously (17, 18) . CBt-PMN (30 mg kg −1 per day), bexarotene (30 mg kg −1 per day) or vehicle (distilled water containing 1% ethanol and 0.5% carboxymethylcellulose) was administered by oral gavage from 2 days before or just before DSS administration. Body weight, drinking water consumption and disease activity index (DAI) score were monitored daily. DAI score was determined according to previously reported criteria (19) based on body weight loss (0: no loss; 1: 1-5%; 2: 5-10%; 3: 10-20%; 4: loss of more than 20%), stool consistency (0: normal; 2: loose; 4: diarrhea) and hematochezia (0: negative occult blood; 2: positive occult blood; 4: gross bleeding). Fecal occult blood was examined using ColoScreen-ES (Helena Laboratories, Beaumont, TX, USA).
Histology
Colonic tissue samples were fixed overnight in 10% formalin neutral buffer solution Mildform 10N (Wako Pure Chemical Industries: Wako, Tokyo, Japan). After fixation, the samples were embedded in paraffin and then cut into 3-µm sections. The sections were deparaffinized, rehydrated and stained with hematoxylin (Agilent Technologies, Santa Clara, CA, USA) and eosin (Wako). The specimens were examined histologically for scoring the degree of colitis on the basis of the following criteria in a blinded manner: crypt architecture, inflammatory cell infiltration and goblet cell depletion.
Preparation of immune cells
Colonic lamina propria cells were treated with HBSS (Nacalai Tesque, Kyoto, Japan) containing 1 mM dithiothreitol, 20 mM ethylenediaminetetraacetic acid (EDTA) and 12.5 mM HEPES at 37°C for 20 min on a stirrer. The tissues were then minced and dissociated in RPMI-1640 containing 0.5 mg ml −1 collagenase (Wako), 0.125 mg ml −1 DNase I, 2% fetal calf serum (FCS), 100 U ml −1 penicillin, 100 µg ml −1 streptomycin and 20 mM HEPES at 37°C for 30 min to obtain single-cell suspensions, which were then subjected to flow cytometry analysis. 
Isolation of colonic epithelial cells
Colonic epithelial cells were isolated as described previously (20) . Briefly, colonic tissues were treated with HBSS containing 1 mM dithiothreitol and 30 mM EDTA on ice for 20 min. Intestinal epithelial sheets were stripped using a 1-ml plastic syringe equipped with a 26-gauge fine needle. The stripped epithelial sheets were washed with ice-cold HBSS and lysed in TRIzol (Thermo Fisher Scientific, Waltham, MA, USA) to purify total RNA before subjecting it to quantitative RT-PCR analysis.
Flow cytometry and cell sorting
Colonic lamina propria cells were incubated with anti-mouse CD16/CD32 antibodies (93; BioLegend, San Diego, CA, USA) to block the Fc receptors, and then stained using antibodies conjugated with Alexa Fluor 488, phycoerythrin (PE), PE-Cy7, PE-CF594, allophycocyanin (APC), APC-Cy7, redFluor 710, eFluor 450, Brilliant Violet (BV) 510 or BV 605. Anti-CD11c (HL3), anti-Ly6C (AL-21), anti-T-bet (O4-46) and anti-RORγt (Q31-378) antibodies were obtained from BD Biosciences (San Jose, CA, USA); anti-CD45 (30-F11), anti-CX 3 CR1 (SA011F11) and anti-B220 (RA3-6B2) antibodies were obtained from BioLegend. Anti-CD3 (7A2), anti-CD4 (RM4-5) and anti-Ly6G (1A8) antibodies were procured from Tonbo Biosciences (San Diego, CA, USA), whereas anti-CD11b (M1/70), anti-CD3 (145-2C11), anti-MHCII (M5/114.15.2) and anti-FoxP3 (FJK-16s) antibodies were procured from Thermo Fisher Scientific. 7-amino-actinomycin D (BioLegend) was added to the cell suspensions to label dead cells. For intracellular staining of FoxP3, T-bet and RORγt, the cells were fixed, permeabilized and stained with anti-FoxP3, anti-T-bet and anti-RORγt antibodies using the Foxp3/Transcription Factor Staining Buffer Set (Thermo Fisher Scientific) after staining for surface antigens. Dead cells were detected using Fixable Viability Stain 780 (BD Biosciences) for intracellular staining. The cells were analyzed using the LSR II flow cytometer (BD Biosciences) to profile the frequency of several immune cell subsets. In separate experiments, monocytes, neutrophils, macrophages, dendritic cells, B cells and T cells were sorted by a FACSAria III (BD Biosciences).
Culture of bone marrow-derived macrophages
Bone marrow cells were isolated from the femurs and tibias of mice. Cells were seeded in 12-well plates at a density of 5 × 10 5 cells ml −1 in RPMI-1640 medium containing 10% FCS, 10 mM HEPES, 20 µM GlutaMAX I (Thermo Fisher Scientific), 55 µM 2-mercaptoethanol (Thermo Fisher Scientific), 100 U ml −1 penicillin, 100 µg ml −1 streptomycin and macrophage colonystimulating factor (BioLegend) for 6 days to generate bone marrow-derived macrophages (BMDMs). The medium in the wells was replaced with fresh medium on day 3. BMDMs were treated with lipopolysaccharide (LPS; 100 ng ml 
Quantitative RT-PCR
Total RNA from colonic tissues, sorted cells and BMDMs was obtained using the RNeasy Mini Kit (Qiagen, Hilden, Germany) or TRIzol, according to the manufacturers' protocols. The samples were reverse-transcribed using iScript Advanced cDNA Synthesis Kit for RT-PCR (Bio-Rad Laboratories, Hercules, CA, USA), and the synthesized cDNA was used as a template for quantitative RT-PCR experiments with SsoFAST EvaGreen Supermix and analyzed on the CFX96 Real-time system and CFX Manager software (Bio-Rad Laboratories). Relative expression levels were calculated by the ΔΔCt method, using Actb as a reference gene. All primers were purchased from Hokkaido System Science (Sapporo, Japan). The sequences of the primer sets are available upon request.
Enzyme-linked immunosorbent assay
Culture media of BMDMs were collected and centrifuged at 20 000 × g for 1 min. The supernatants were aliquoted and stored at −80°C until analysis. The concentration of IL-6 and TNF-α was measured using ELISA kits (BioLegend), according to the manufacturers' protocol.
Luciferase reporter gene assay
Luciferase reporter gene assays were performed as described previously (17) . Briefly, a tk-PPRE×3-Luc plasmid containing PPARδ responsive element and NX3′ × 3-tk-Luc plasmid containing Nur77 response elements were used in the reporter gene assay for PPARδ/RXRα and Nur77/RXRα, respectively. In addition to one of these reporter plasmids (4.0 µg), expression vectors for RXRα (0.5 µg), together with either PPARδ (0.5 µg) or Nur77 (0.5 µg), were transfected into COS-1 cells using Effectene transfection reagent (Qiagen) following the manufacturer's protocol.
Statistical analysis
Values are expressed as the mean ± SD or SEM. Differences between two groups were analyzed by the Student's t-test. When variances were not homogeneous, the data were analyzed by the Mann-Whitney U-test. Differences between three or more groups were analyzed by one-way analysis of variance test, followed by Dunnett's test. GraphPad Prism version 7 was used for all statistical analyses. Differences were considered statistically significant when P values were <0.05.
Results
CBt-PMN ameliorates DSS-induced colitis
We examined the effect of the RXR partial agonist CBt-PMN on DSS-induced colitis, an experimental animal model of IBD. Administration of 2% DSS caused body weight loss, diarrhea and bloody stools. However, these symptoms were less severe in the CBt-PMN-treated group compared to the control group (Fig. 1A and B) . Colon shortening reflects colonic inflammation in this disease model. Colon length was significantly longer in mice from the CBt-PMN-treated group (Fig.  1C and D) . Moreover, histological analysis showed crypt loss, inflammatory cell infiltration and goblet cell depletion in the control group; however, these pathological changes were less severe for mice in the CBt-PMN-treated group (Fig. 1E  and F) . Expression of pro-inflammatory cytokines in colonic tissue was examined by quantitative RT-PCR, which showed significant down-regulation of Tnf, Il6 and Il17a in the CBt-PMN-treated group compared with the control group (Fig.  1G) . Expression of Il1b also tended to decrease in the CBt-PMN-treated group; however, the difference was not statistically significant (Fig. 1G) . Further, we analyzed the expression of Cxcl1 and Cxcl2 which are genes of chemokines inducing neutrophil recruitment in colonic tissue (21) . These chemokines were down-regulated in the CBt-PMN-treated group (Fig. 1H) . Of note, CBt-PMN did not cause hepatomegaly, an adverse effect observed in the mice treated with the conventional RXR agonist, bexarotene (Supplementary Figure 1) . Collectively, these results indicate that oral administration of CBt-PMN suppresses DSS-induced colitis without the adverse effect.
Effect of CBt-PMN on immune cell subsets of the colonic lamina propria
Several immune cell types infiltrating into the gut mediate the development of IBD as well as DSS-induced colitis (22, 23) . In particular, inflammatory myeloid cells such as monocytes and neutrophils contribute to the development of colitis. To investigate whether CBt-PMN affects the composition of immune cells, we performed flow cytometric analysis of cells Fig. 1 . Effect of CBt-PMN on DSS-induced colitis. (A-H) Mice were treated with 2% DSS until day 6 and were then given water until day 9. The RXR partial agonist CBt-PMN (30 mg kg −1 per day) or vehicle was administered from 2 days before DSS treatment initiation. Body weight (A) and DAI score (B) were monitored daily. The colon length was measured at day 9 (C, D) and sections of distal colonic tissues were subjected to H&E staining (E). Scale bars: 5 cm (C), 100 µm (E). The histological score was calculated based on the criteria described in the Methods section (F). Values are presented as mean ± SD (n = 4-6). Data are representative of two or four independent experiments. Expression levels of pro-inflammatory cytokines and chemokines in the colonic tissue were analyzed by quantitative RT-PCR (G, H). The values were normalized to the expression of Actb. Values are presented as mean ± SEM (n = 13-14) from three independent experiments. *P < 0.05, **P < 0.01 (Student's t-test or Mann-Whitney U-test). n.s.: not significant. from colonic lamina propria of mice with colitis that were treated with CBt-PMN or vehicle (Fig. 2A) . The proportion of neutrophils was significantly lower in the CBt-PMN-treated group compared to the control group. There was no significant difference in the frequency of T cells, B cells, dendritic cells, macrophages and Ly6C hi monocytes between the two groups (Fig. 2B) . There was no significant difference in the number of these cell populations (Fig. 2C) . We further analyzed the subpopulations of T cells. There was no significant difference in the frequency of Foxp3 + (Treg) and T-bet + (Th1) CD4 + T cells between the two groups, whereas that of T h 17 cells was higher in the CBt-PMN-treated group than the control group (Supplementary Figure 2A) . The number of T h 1 cells and T h 17 cells was also higher in the CBt-PMN-treated group (Supplementary Figure 2B) . Given that Il17a expression was significantly down-regulated in the colon of CBt-PMN-treated group (Fig. 1G) , CBt-PMN may suppress the function of T h 17 cells.
We next considered the possibility that CBt-PMN directly affects various immune cells. To address this possibility, we examined the gene expression of Rxra in Ly6C hi monocytes, macrophages, neutrophils, dendritic cells, B cells and T cells from the colonic lamina propria and blood under steady state or DSS-induced colitis conditions. Ly6C hi monocytes and neutrophils exist in inflamed but not non-inflamed area. Thus, these cell populations from blood were analyzed under steady state circumstances. In both conditions, Rxra was highly expressed in Ly6C hi monocytes (Fig. 3A) . These results show that CBt-PMN is likely to have effects on Ly6C hi monocytes. Ly6C hi monocytes migrate from blood vessels to the colonic tissue to exacerbate inflammation by abundantly producing pro-inflammatory cytokines (e.g. TNF-α, IL-1β and IL-6) in mouse models of DSS-induced colitis (22) . Ly6C hi monocytes are regarded as major effectors responsible for inflammatory responses in this model, because removal of Ly6C hi monocytes was shown to prevent the development of colitis (22) . Although CBt-PMN did not change the number of Ly6C hi monocytes, we considered the possibility that CBt-PMN affects the function of these cells. This is supported by the observation that Rxra was highly expressed in these cells. To investigate this possibility, we sorted Ly6C hi monocytes from the colonic lamina propria of DSS-treated mice and analyzed the expression of pro-inflammatory cytokines. We observed that the expression of Il6 was significantly decreased in the CBt-PMN-treated group compared to that in the control group (Fig. 3B) . Furthermore, the expression of Tnf also tended to be decreased in the CBt-PMN-treated group (Fig. 3B) . We also sorted macrophages, neutrophils and dendritic cells and analyzed Il6 expression. The expression of Il6 in macrophages was also down-regulated in the CBt-PMN-treated group (Supplementary Figure 3) . However, Il6 expression in neutrophils and dendritic cells was comparable between the two groups (Supplementary Figure 3) .
Effect of CBt-PMN on colonic epithelial cells
We further explored the effect of CBt-PMN on colonic epithelial cells, which serve as a physicochemical barrier at the mucosal surface by forming a tight junction (Tj) (24) . Tj is a multiprotein junctional complex that establishes a physiological barrier at the mucosal surface. The effect of CBt-PMN on the colonic epithelial Tj barrier in the epithelial cells was evaluated by expression levels of Cldn1 and Tjp1 encoding Tj proteins. There was no significant difference in the expression of Cldn1 and Tjp1 between the CBt-PMN-treated group and the control group (Supplementary Figure 4A) . TNF-α is a pro-inflammatory cytokine in the pathogenesis of IBD and DSS-induced colitis (25, 26) and also disrupts the epithelial Tj barrier (27) (28) (29) . The blockade of TNF receptor (TNFR) 1 and/or TNFR2 has been shown to be sufficient for inhibition of inflammation in experimental colitis (30) . In this study, the expression levels of Tnfrsf1a and Tnfrsf1b encoding TNFR1 and TNFR2, respectively, were comparable between the two groups (Supplementary Figure 4B) . These results suggest that CBt-PMN has little impact on the colonic epithelial cells.
Identification of RXR-associated molecules responsible for anti-inflammatory effects
It is well documented that RXR-permissive heterodimers are activated upon ligand binding to RXR. Therefore, CBt-PMN may also potentially activate heterodimers with anti-inflammatory properties. To explore this possibility, we initially sought to clarify the expression profile of genes encoding the three isoforms of RXR (Rxra, Rxrab and Rxrg) and other nuclear receptors that are known to form a heterodimer with RXR, in Ly6C hi monocytes. As shown in Fig. 2(A) , Ly6C hi monocytes from the colonic lamina propria of DSS-treated mice expressed Rxra, Nr4a1, Nr4a2, Nr1h2, Nr1h3, Nr1i3, Ppard, and Pparg (Fig. 3C) . Meanwhile, Rxrb, Rxrg, Nr1h4, Nr1h5, Nr1i2 and Ppara were undetectable in Ly6C hi monocytes. A similar expression profile of nuclear receptors was also observed in BMDMs (Fig. 3C) . Therefore, we employed BMDMs to assess the mode of action of CBt-PMN in vitro. We first confirmed that CBt-PMN significantly repressed LPSdependent IL-6 production by BMDMs at both mRNA and protein levels ( Fig. 4A and B) .
To identify RXR heterodimers that mediate the anti-inflammatory effects of CBt-PMN, we examined the effect of various agonists specific for the nuclear receptors expressed by BMDMs on LPS-dependent IL-6 production. As mentioned previously, BMDMs and Ly6C hi monocytes expressed Nr4a1 (Nur77), Nr4a2 (Nurr1), Nr1h2 (LXRβ), Nr1h3 (LXRα), Nr1i3 (CAR), Ppard (PPARδ) and Pparg (PPARγ). BMDMs were treated with LPS and each specific agonist at concentrations of 5, 10 or 20 µM, which are at least 10-fold higher than their EC 50 values. Of note, we could not analyze the effect of Nurr1, because of the absence of commercially available agonists. Notably, activation of PPARδ and Nur77 suppressed the production of IL-6 in a concentration-dependent manner ( Fig.  4C and D) . These inhibitions did not result from the cytotoxic effect of agonists (data not shown). In sharp contrast, activation of LXR, CAR and PPARγ did not affect IL-6 production ( Fig. 4E-G) .
Additionally, CBt-PMN significantly suppressed LPSdependent TNF-α production by BMDMs at mRNA as well as protein levels in a concentration-dependent manner ( Fig.  5A and B) . Likewise, activation of PPARδ and Nur77 also decreased the TNF-α production, albeit at a lesser extent compared to the effect of CBt-PMN (Fig. 5C and D) . These data raised the possibility that the anti-inflammatory activity of CBt-PMN is attributed to dual activation of PPARδ/RXR and Nur77/RXR. To examine this possibility, we performed a luciferase reporter gene assay using COS-1 cells that express either PPARδ/RXR or Nur77/RXR, in addition to their responsive elements followed by luciferase. PPARδ/RXR-expressing cells treated with CBt-PMN (0.1-10 µM) showed significantly up-regulated luciferase activity in a concentration-dependent manner (Fig. 6A) . Luciferase activity was also moderately Fig. 3 . Effect of CBt-PMN on the expression of pro-inflammatory cytokines in colonic tissue-infiltrating monocytes. (A) The expression level of Rxra was analyzed in various immune cell subsets at steady and inflammatory states. (B, C) Monocytes were isolated from the colonic lamina propria of mice treated with CBt-PMN or vehicle at day 9 after the initiation of DSS administration. The mRNA expression levels of pro-inflammatory cytokines (B) were analyzed. Values are presented as mean ± SEM (n = 8-10) from two independent experiments. *P < 0.05 (MannWhitney U-test). n.s.: not significant. Expression levels of RXR subtypes and RXR-associating nuclear receptors were analyzed in monocytes from the colonic lamina propria of DSS-treated mice at day 9 and in BMDMs (C). Values are presented as mean ± SD (n = 3-4). The values were normalized to that of Actb. n.d.: not detected.
but significantly, up-regulated in Nur77/RXR-expressing cells after treatment with CBt-PMN (Fig. 6B) . Consistent with these results, we observed up-regulation of Lpcat3 and Ikbke, which are well documented as targets of PPARδ/RXR and Nur77/RXR, respectively, in BMDMs (Fig. 6C) . Together, these data support the notion that CBt-PMN exerts anti-inflammatory activity by dual activation of PPARδ/RXR and Nur77/RXR.
Discussion
In this study, we found that oral administration of the RXR partial agonist CBt-PMN protects from the development of DSS-induced colitis. Ly6C hi monocytes are considered as major effector cells responsible for inflammatory responses in this model (22) . Ly6C hi monocytes mainly circulate in the bloodstream under physiological conditions. Upon DSS treatment, this cell population migrates to colonic tissue and abundantly produces an array of inflammatory cytokines including IL-1β, IL-6 and TNF-α (22, 31) . Intriguingly, administration of CBt-PMN did not significantly affect the number of Ly6C hi monocytes in the colon; however, it down-regulated the expression levels of Il6 and Tnf in these cells. These results suggest that the anti-inflammatory effect of RXR activation by the partial agonist can be attributed to the alleviation of activity in Ly6C monocytes, rather than prevention of the development and/or migration of these cells. IL-6 contributes to the pathogenesis of DSS-induced colitis (32) . IL-6 induces NF-κB activation to enhance the expression of intercellular adhesion molecule 1 (ICAM-1), which accelerates inflammatory responses in IBD by enhancing leukocyte migration (33, 34) . In support of this, IL-6-deficient mice are resistant to the development of DSSinduced colitis compared to wild-type mice, owing to attenuated STAT3 signaling, which is important for the maintenance of inflammation (35) . TNF-α is another major effector cytokine that mediates the development of DSS-induced colitis (32) . This cytokine disrupts the integrity of intestinal epithelium by altering the arrangement of adhesion proteins and inducing apoptotic death in enterocytes. TNF-α also promotes the pro-inflammatory activity of mucosa-infiltrating mononuclear cells (36) . Blockade of both IL-6 and TNF-α by monoclonal antibodies dramatically improves the histological score in DSS-induced colitis (32) . Collectively, activation of RXR by CBt-PMN may interrupt the inflammatory circuit by repressing the expression of these pro-inflammatory cytokines.
Macrophages also contribute to the development of gut inflammation. Ly6C hi monocytes migrating to colonic tissue differentiate into pro-inflammatory macrophages with high expression of Il6 (22) . Reduction of IL-6 production by macrophages is associated with amelioration of DSS-induced colitis (37) . We observed that colonic macrophages also express a substantial level of Rxra. Therefore, CBt-PMN may directly down-regulate Il6 expression in macrophages to suppress DSS-induced colitis. CBt-PMN treatment also down-regulated Cxcl1 and Cxcl2 expression in the colon. Given that mainly macrophages produce CXCL1 and CXCL2 upon inflammatory stimuli (38, 39) , CBt-PMN may suppress production of these chemokines in macrophages. RXR forms heterodimers with a variety of nuclear receptors. We observed that BMDMs and Ly6C hi monocytes express seven potential RXR partners. Previous work demonstrated that PPARγ and RXR agonists reduced TNF-α and IL-1β mRNA levels in 2,4,6-trinitrobenzene sulfonic acid-treated mice (40) . On the other hand, several other reports showed that PPARγ is down-regulated in colonic tissue, peritoneal exudate cells and lamina propria lymphocytes during the course of DSSinduced colitis (41, 42) . We also observed that the expression level of Pparg in monocytes is lowest among the seven RXR partners expressed in this cell subset. Furthermore, activation of the PPARγ/RXR heterodimer failed to suppress inflammatory cytokine production by BMDMs. Thus, PPARγ/ RXR is unlikely to be a significant target of CBt-PMN.
In contrast, PPARδ/RXR and Nur77/RXR possessed antiinflammatory properties. Hence, we consider that CBt-PMN suppresses LPS-dependent inflammatory responses in BMDMs by concomitantly activating these permissive heterodimers. This view was corroborated by the observation that CBt-PMN enhanced the transcriptional activity of the reporter gene under the PPARδ/RXR or Nur77/ RXR-binding element. Furthermore, CBt-PMN up-regulated the target molecules of these heterodimers. The PPARδ/RXR heterodimer has been suggested to facilitate nuclear translocation of B-cell lymphoma 6 (Bcl-6), a transcriptional repressor for pro-inflammatory cytokines (43) , in mouse peritoneal macrophages. This mechanism may also be required for the PPARδ/RXR-dependent suppression of inflammatory responses in BMDMs because Bcl-6 deficiency in BMDMs markedly increases their IL-6 expression (44). Meanwhile, overexpression of Nur77 is known to potently inhibit IL-1β-or TNF-α-induced activation of NF-κB, and thereby down-regulates pro-inflammatory cytokines and chemokines in human peripheral blood monocytes as well as in the THP-1 monocyte/macrophage cell line (45, 46) . Considering our observations together with previous reports, dual activation of PPARδ/RXR and Nur77/RXR through the permissive mechanism may synergistically mitigate the pro-inflammatory response of monocyte/macrophages through at least two different mechanisms, namely, nuclear translocation of Bcl-6 and inhibition of NF-κB signaling. Further investigation is necessary to ascertain this concept.
Relative to DMSO
Luciferase Units Relative to DMSO Luciferase Units In conclusion, we revealed that the partial RXR agonist, CBt-PMN, efficiently ameliorates intestinal inflammation, at least in part, by alleviating the inflammatory response of monocytes, through activation of PPARδ/RXR and Nur77/ RXR heterodimers. On the basis of these data, we consider CBt-PMN as a promising drug candidate for IBD with minimal adverse effects. 
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